Danaher (NYSE:DHR) gets a new price target of $290.00 at Citigroup

Danaher (NYSE:DHR – Free Report) The price target was raised by Citigroup from $280.00 to $290.00 in a research note released on Wednesday, Benzinga reports. The brokerage currently has a buy rating on the conglomerate’s shares.

A number of other stock analysts have also recently weighed in on DHR. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. HSBC raised shares of Danaher from a hold rating to a buy rating and raised their price target for the company from $250.00 to $280.00 in a research note on Wednesday, April 17. Barclays raised its price target on shares of Danaher from $260.00 to $270.00 and gave the company an equal-weight rating in a research note on Wednesday. Raymond James raised their price target on shares of Danaher from $240.00 to $270.00 and gave the company an outperform rating in a research note on Wednesday, January 31. Finally, TD Cowen raised its price target on shares of Danaher from $280.00 to $290.00 and gave the company a buy rating in a research note on Wednesday. Six investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of Moderate Buy and an average target price of $270.00.

Get our latest report on Danaher

Danaher shares fall 1.1%

Shares of Danaher opened at $250.41 on Wednesday. The company has a current ratio of 1.68, a quick ratio of 1.37 and a debt-to-equity ratio of 0.31. The company has a fifty-day moving average of $249.00 and a 200-day moving average of $230.78. The stock has a market cap of $185.44 billion, a price-to-earnings ratio of 39.19, a price-to-earnings growth ratio of 3.96 and a beta of 0.83. Danaher has a 12-month low of $182.09 and a 12-month high of $259.00.

Danaher (NYSE:DHR – Get Free Report) last posted its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The company had revenue of $5.80 billion during the quarter, compared to analyst expectations of $5.62 billion. Danaher had a net margin of 17.26% and a return on equity of 12.25%. The company’s revenue fell 2.6% year over year this quarter. During the same period last year, the company posted earnings per share of $2.36. Equities research analysts predict that Danaher will post earnings per share of 7.62 for the current fiscal year.

Danaher increases dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, April 26. Shareholders of record on Thursday, March 28 will receive a dividend of $0.27. This is a boost from Danaher’s previous quarterly dividend of $0.24. The ex-dividend date is Wednesday, March 27. This represents a dividend of $1.08 annually and a yield of 0.43%. Danaher’s dividend payout ratio is 16.90%.

Insiders place their bets

In other news, SVP Daniel Raskas sold 23,757 shares of the stock in a transaction that occurred on Monday, February 26th. The shares sold at an average price of $252.00, for a total value of $5,986,764.00. Following the completion of the transaction, the senior vice president now directly owns 38,102 shares of the company’s stock, valued at $9,601,704. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, SVP Georgeann Couchara sold 2,622 shares of the stock in a transaction that occurred on Tuesday, February 13th. The shares sold at an average price of $242.67, for a total value of $636,280.74. Following the completion of the transaction, the senior vice president now directly owns 4,244 shares of the company’s stock, valued at $1,029,891.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Daniel Raskas sold 23,757 shares of the stock in a transaction that occurred on Monday, February 26. The shares were sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the completion of the transaction, the senior vice president now owns 38,102 shares of the company’s stock, valued at $9,601,704. The explanation of this sale can be found here. In the last 90 days, insiders have sold 32,957 company shares worth $8,265,802. Insiders own 10.90% of the company’s shares.

Institutional trading in Danaher

A number of major investors have recently increased or decreased their stakes in DHR. Cape Investment Advisory Inc. bought a new stake in Danaher worth about $25,000 in the fourth quarter. Tsfg LLC grew its holdings in Danaher by 733.3% during the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after purchasing an additional 88 shares in the last quarter. BKM Wealth Management LLC bought a new stake in Danaher in the fourth quarter worth approximately $27,000. Wetzel Investment Advisors Inc. bought a new stake in Danaher worth about $29,000 in the fourth quarter. Finally, OFI Invest Asset Management bought a new stake in Danaher stock in the third quarter worth approximately $30,000. 79.05% of the shares are currently held by institutional investors.

Danaher Company Profile

(Get a free report)

Danaher Corporation designs, manufactures and sells professional, medical, industrial and commercial products and services worldwide. The Biotechnology segments offer bioprocess technologies, consumables and services that advance, accelerate and integrate the development and production of therapies; Cell line and cell culture media development services; cell culture media, process fluids and buffers for production, chromatography resins, filtration technologies, aseptic fill finishing; single-use hardware and consumables and services, such as the design and installation of full production suites; laboratory filtration, separation and purification; laboratory-scale protein purification and analytical tools; reagents, membranes and services; and filtration solutions for healthcare.

read more

Get daily news and reviews for Danaher – Enter your email address below to receive a daily digest of the latest news and analyst ratings for Danaher and affiliates with MarketBeat.com’s FREE daily email newsletter.